Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka, Japan

Kinoshita, Fukuaki Lee; Ito, Yuri; Morishima, Toshitaka; Miyashiro, Isao; Nakayama, Tomio

doi:10.1093/jjco/hyx094

Cited by 35 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gender survival analysis of our cohort is in agreement with previous reports on gender survival difference in lung cancer, which revealed consistently improved survival for female patients [26][27][28][29][30]. In this study, the median overall survival for female patients with ESRD is 12.25 months (95% CI: 5.78-17.45) comparable to the 14.13 months (95% CI: 11.07-16.43) for female patients without ESRD, p = 0.996.…”

Section: Discussionsupporting

confidence: 92%

Appraisal of lung cancer survival in patients with end-stage renal disease

Chen

Yang

et al. 2019

Arch Med Sci

View full text Add to dashboard Cite

Introduction: The survival outcome of lung cancer patients with end-stage renal disease has been poorly studied in the literature. In this study, we evaluated the effect of end-stage renal disease on lung cancer survival. Material and methods: A retrospective, multicenter, matched-cohort study of lung cancer patients with end-stage renal disease under renal replacement therapy (WITH-ESRD) and without end-stage renal disease (WITH-OUT-ESRD) was performed. One WITH-ESRD patient was matched to four WITHOUT-ESRD patients. Results: Baseline clinical characteristics did not differ statistically significantly after matching between the WITH-ESRD and WITHOUT-ESRD groups. WITH-ESRD included 133 patients and WITHOUT-ESRD included 532 patients. Kaplan-Meier survival analysis demonstrated no significant difference in median overall survival between WITH-ESRD patients and WITHOUT-ESRD patients (7.36 months versus 12.25 months, respectively, p = 0.133). Lung cancer WITH-ESRD patients receiving medical treatment had a median overall survival of 5.98 months (95% CI: 4.34-11.76) compared to 14.13 months (95% CI: 11.30-16.43) for WITHOUT-ESRD patients, p = 0.019. Although patients receiving surgical treatment compared to those receiving medical treatment had an improvement of survival by 46% (HR = 0.54, 95% CI: 0.19-1.53, p = 0.243), the difference did not reach statistical significance. Cox regression analysis revealed that male gender and stage IIIA-IV were independent factors associated with poor outcome for WITH-ESRD patients. Conclusions: In our limited experience, the survival for lung cancer with ESRD is not inferior to lung cancer patients without ESRD. The reasons for poor survival for the WITH-ESRD medical treatment group and late diagnosis despite frequent medical visits merit further investigation.

show abstract

Section: Discussionsupporting

confidence: 92%

Appraisal of lung cancer survival in patients with end-stage renal disease

Chen

Yang

et al. 2019

Arch Med Sci

View full text Add to dashboard Cite

show abstract

“…LC survival is higher in women than in men [6][7][8], and for non-small cell lung cancer (NSCLC) than for small cell lung cancer (SCLC) [6,9]. Survival declines with advancing age [6] and is strongly dependent on stage at diagnosis [9,10].…”

Section: Introductionmentioning

confidence: 99%

Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016

et al. 2019

View full text Add to dashboard Cite

Background: Lung cancer (LC) remains the most frequent cause of cancer death worldwide. We aimed to examine long-term trends in LC survival in Estonia by age, gender, histologic type and stage, with specific focus on surgical treatment. Material and methods: Data on all incident cases of LC diagnosed from 1996 to 2016 were obtained from the Estonian Cancer Registry. Logistic regression was used to examine receipt of surgical treatment in localized LC. Relative survival ratios (RSR) were calculated, and excess hazard ratios (EHR) of death were estimated by stage with gender, age, histology and period of diagnosis as independent variables. Results: Among the total of 16,423 cases, squamous cell carcinoma remained the most common histologic type. The odds of receiving surgical treatment in localized LC increased significantly over time and were associated with age, gender and histologic type. Overall, the age-standardized 5-year RSR improved significantly from 10% in 1996-2002 to 16% in 2010-2016 (from 8% to 15% in men and from 15% to 20% in women). Larger survival gain was seen in younger patients, for non-small cell LC subtypes, and for surgically treated patients. For localized disease, the 5-year RSR increased by more than 20 percentage units, reaching 50% in men and 69% in women. For all stages, the adjusted EHR of death was significantly associated with age, histologic type and period of diagnosis. Conclusions: We observed a substantial improvement of relative survival, with considerable variations across patient groups. After adjustment for age, gender and histology, a significant survival increase over time was seen for all stages. The considerable survival gain observed for localized LC can largely be attributed to rapidly growing proportion of surgically treated patients. Further investigation of LC management practices, particularly the use of non-surgical treatment options is warranted.

show abstract

“…Several studies have reported gender differences in lung cancer survival . According to Wisnivesky et al ., women have better lung cancer‐specific, overall, and relative survival than men in all treatment groups .…”

Section: Discussionmentioning

confidence: 99%

“…22 Several studies have reported gender differences in lung cancer survival. [23][24][25] According to Wisnivesky et al, women have better lung cancer-specific, overall, and relative survival than men in all treatment groups. 24 The genderrelated differences in cancer affecting both sexes are more prominent in lung cancer at localized, regional, and unknown stages.…”

Section: Discussionmentioning

confidence: 99%

Lung cancer outcome in the setting of chronic kidney disease: Does the glomerular filtration estimation formula matter?

Chen

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe survival outcomes of lung cancer patients with coexisting chronic kidney disease (CKD) reported in the literature have been conflicting. We evaluate whether the survival of lung cancer patients with and without CKD differ significantly using two different formulas.MethodsA retrospective, multicenter, propensity‐matched study of lung cancer patients with and without CKD was conducted. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/minute. Kaplan–Meier survival analysis was used to determine survival differences between CKD and non‐CKD patients using the Cockcroft–Gault formula (CKD–CG) compared to the Chronic Kidney Disease Epidemiology Collaboration Formula (CKD‐EPI).ResultsBaseline clinical characteristics did not differ statistically significantly between the groups. The CKD‐CG formula demonstrated median survival of 10.61 months (95% confidence interval [CI] 9.33–11.89) for the non‐CKD group compared to 10.58 months (95% CI 9.03–12.13) for the CKD group (P = 0.76). The CKD‐EPI formula demonstrated median survival of 9.10 months (95% CI 8.01–10.20) for the non‐CKD group compared to 7.59 months (95% CI 6.50–8.68) for the CKD group (P = 0.19). Cox regression analysis using both models revealed that CKD is not an independent risk factor for mortality in lung cancer patients. Although the CKD‐EPI formula revealed an increased risk of mortality and the CKD‐CG formula revealed decreased survival, these results were not statistically significant.ConclusionLung cancer survival did not differ significantly between CKD and non‐CKD patients using either formula.

show abstract

Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka, Japan

Cited by 35 publications

References 32 publications

Appraisal of lung cancer survival in patients with end-stage renal disease

Appraisal of lung cancer survival in patients with end-stage renal disease

Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016

Lung cancer outcome in the setting of chronic kidney disease: Does the glomerular filtration estimation formula matter?

Contact Info

Product

Resources

About